Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use ...

Vancouver, Canada, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of a U.S. patent application by the United States Patent and Trademark Office (USPTO) for its innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, s ...

TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of a U.S. patent application by the United States Patent and Trademark Office. The patent relates to an innovative combin ...

Core Insights - Clearmind Medicine Inc. successfully held its inaugural Annual Scientific Advisory Board (SAB) meeting, gathering eight experts in relevant fields to provide strategic guidance on the company's clinical and preclinical programs [1][2]. Group 1: Clinical Development - The SAB focused on Clearmind's lead candidate, 5-Methoxy-2-aminoindane (MEAI), which is currently in Phase 1/2a clinical trials for Alcohol Use Disorder (AUD) [2]. - MEAI was highlighted for its unique pharmacological profile and promising safety data, suggesting potential advantages over emerging GLP-1 therapies, making it a potentially safe, accessible, and cost-effective treatment option [2]. - Preclinical findings indicate MEAI's potential to address not only AUD but also obesity, metabolic syndrome, and mental health challenges faced by veterans [2]. Group 2: Strategic Opportunities - The SAB explored opportunities to strengthen Clearmind's clinical development and potential partnerships, reviewing the company's robust intellectual property portfolio, which includes 31 granted patents worldwide [3]. - Insights from the SAB will guide the company's development strategy as it aims to deliver transformative psychedelic-derived therapies for global health challenges [3]. Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to address major under-treated health problems, including alcohol use disorder [4]. - The company's intellectual property portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents and acquire more intellectual property as needed [5].

Core Points - Clearmind Medicine Inc. has entered into securities purchase agreements with institutional investors to issue convertible promissory notes totaling up to $10 million [1][3] - The initial closing involved the issuance of notes worth $555,556 for a purchase price of $500,000 [1] - The company plans to use the proceeds from the notes for working capital, general corporate purposes, and potential acquisitions [3] Group 1 - The company will issue additional notes worth $1,944,444 for a purchase price of $1,750,000 after the effectiveness of a registration statement [3] - Clearmind may request additional purchases of notes up to $2,500,000 per quarter, totaling $7,500,000, starting three months after the second initial closing [3][4] - Each note will be issued at 90% of the principal amount, accruing interest at 4%, increasing to 14% upon default, and is to be repaid in ten equal monthly installments starting 18 months after issuance [5] Group 2 - Clearmind is focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [6] - The company holds a portfolio of nineteen patent families with 31 granted patents and aims to acquire additional intellectual property [6] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [7]

Core Viewpoint - Clearmind Medicine Inc. has announced the publication of an international patent application for a combination therapy aimed at treating metabolic syndrome and obesity, in collaboration with SciSparc Ltd. [1][2] Group 1: Patent and Collaboration - The patent application covers a combination therapy of Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) [2] - This collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China [4] - The focus of the collaboration is on developing therapies that combine neuroplastogens with N-acylethanolamines to address various health disorders [4] Group 2: Health Impact and Market Potential - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The proprietary combination therapy aims to leverage MEAI's pharmacological profile and PEA's anti-inflammatory properties to provide a safe and effective treatment for these health challenges [3] Group 3: Company Strategy and Intellectual Property - The company is committed to developing breakthrough therapies for complex health conditions, with a focus on metabolic syndrome and obesity [5] - Clearmind's intellectual property portfolio currently consists of 19 patent families, including 31 granted patents, with plans to seek additional patents as warranted [6]

Core Insights - SciSparc Ltd. has announced a collaboration with Clearmind Medicine Inc. that has resulted in the publication of an international patent application under the Patent Cooperation Treaty (PCT) [1] - The patent application covers a combination therapy of Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) aimed at treating metabolic syndrome and obesity [2] - Metabolic syndrome affects up to one-third of U.S. adults, increasing the risk of serious health issues such as heart disease and type 2 diabetes [3] - The collaboration has led to the filing of 13 patent families across multiple jurisdictions, focusing on innovative therapies for mental health disorders and metabolic conditions [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing cannabinoid-based therapies, with ongoing programs targeting Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [5] - Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical biotech company dedicated to developing psychedelic-derived therapeutics for health issues like alcohol use disorder, with a portfolio of 19 patent families [6]

Core Insights - Clearmind Medicine Inc. has received Institutional Review Board (IRB) approval from Hadassah Medical Center for its Phase 1/2a clinical trial of CMND-100, aimed at treating Alcohol Use Disorder (AUD) [1][3][4] - The trial will also involve other prestigious institutions such as Yale School of Medicine and Johns Hopkins University [2] - The approval follows previous regulatory milestones, including FDA clearance of the Investigational New Drug (IND) application [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds a portfolio of nineteen patent families with 31 granted patents and plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase 1/2a trial is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption [4] - The global burden of AUD is significant, accounting for 4.7% of all deaths worldwide, highlighting the need for effective treatments [4]

Core Viewpoint - Clearmind Medicine Inc. has filed a new international patent application for a combination therapy aimed at addressing obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to tackle significant health issues, including alcohol use disorder [4] - The company currently holds a portfolio of nineteen patent families, which includes 31 granted patents, and plans to seek additional patents as necessary [5] Health Challenges Addressed - The proprietary combination therapy targets obesity, which affects over 890 million people globally, and MASLD, impacting more than 30% of the adult population [2] - The treatment options for these conditions remain limited despite their widespread prevalence [2] Therapeutic Approach - The combination therapy utilizes MEAI (5-methoxy-2-aminoindane) and Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory and neuroprotective properties [3] - The company believes this novel approach could provide a safe and effective therapeutic alternative for patients [3] Collaboration - The patent filing is part of an ongoing collaboration with SciSparc Ltd., which is also focused on developing therapies for central nervous system disorders [3]

Core Insights - SciSparc Ltd. has filed a new international patent application in collaboration with Clearmind Medicine Inc. for a combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [1][2][3] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio that includes cannabinoid pharmaceuticals [4] - The company is currently developing drugs such as SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus [4] Industry Context - Obesity affects over 890 million people globally and is a significant risk factor for chronic conditions, while non-alcoholic fatty liver disease (NAFLD) impacts more than 30% of the adult population [2] - There is a limited number of treatment options available for these health challenges, highlighting the potential market opportunity for innovative therapies [2]